VTRS News and Press, Viatris Inc. From 01/16/24

2024-01-16 10:50:09 ET Summary Investors are monitoring the S&P 500 stocks as the index starts the year with a pullback and uncertainty over interest rate cuts. Top-performing stocks include Juniper, Nvidia, Eli Lilly, Viatris, and Organon, while solar energy stocks and Boeing...

2024-01-16 08:19:18 ET Orbicular Pharmaceutical Technologies has agreed to resolve its patent fight with Theravance Biopharma ( NASDAQ: TBPH ) and Viatris ( NASDAQ: VTRS ) unit, Mylan, over the respiratory disorder therapy Yupelri. Per the terms of the agreement, Orbicul...

2024-01-16 03:58:00 ET Summary In December 2023, we received $6,884.70 in dividend income. The majority of our dividend income this month came from funds. Johnson & Johnson, Target, and T. Rowe Price were clearly the top 3 individual stock payers. December is alw...

2024-01-14 08:04:48 ET Summary Viatris stock has been on the rise, up over 20% in the past month, reaching its highest price since February 2023. The company's revenues are derived from established brands, generics, and complex generics, with a significant portion coming from pate...

2024-01-12 12:54:48 ET Summary Viatris is an American pharmaceutical company formed as a result of the merger of Mylan and Upjohn. Over the past two and a half months, Viatris' share price has risen by more than 38%. Viatris' dividend yield is 3.97%, which is attractive becaus...

2024-01-12 01:06:36 ET Summary Invesco S&P 500 Pure Value ETF holds large cap value stocks with little or no growth characteristics. It is well-diversified across holdings, but overweight in the financial sector. Valuation metrics look attractive, but RPV has lagged the S&...

2024-01-10 18:50:01 ET Viatris Inc. (VTRS) J.P. Morgan 42nd Annual Healthcare Conference January 10, 2024 01:30 PM ET Company Participants Scott A. Smith - CEO Rajiv Malik - President Sanjeev Narula - CFO Conference Call Participants Chris Schott - J....

2024-01-10 15:35:59 ET More on Viatris Viatris Stock Is Dirt Cheap And Worth Buying Viatris: It Is Always Cheap, Yet It Is Always Declining Viatris Inc. 2023 Q3 - Results - Earnings Call Presentation Regeneron gains after mixed ruling in patent suit over Eyle...

2024-01-09 03:16:00 ET Summary In December, we (my wife and I) received a dividend income total of $10,193.04. Crossed the $10k threshold, again. Vanguard’s High Dividend Yield ETF, which we have been buying for 3.5 years, literally has paid immense dividends. In total,...

2024-01-07 12:00:45 ET More on AbbVie, Bristol-Myers, etc. AbbVie: Still Expensive Despite The Great M&A Acumen Bristol-Myers Squibb Company (BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Health...